Nanodone is developing next generation cannabinoid delivery technologies, focused on improving the consistency and predictability of oral formulations.
Our current work explores rapid onset edible formats designed to better align with patient and clinician needs.
As part of our development programme, we are planning an early-stage pharmacokinetic (PK) study to better understand how these formulations are absorbed and processed in the body, including in populations with high unmet need such as those experiencing anxiety-related conditions.
We are building towards regulatory-compliant products intended for use within established medical frameworks in the UK and Europe.
Want to see what it takes to bring a cannabinoid-based product from concept through formulation, testing, and regulatory approval?
Follow our journey as we explore the science, challenges, and opportunities shaping the future of cannabinoid delivery.